Pomalidomide-C5-Dovitinib

Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD+ acute myeloid leukemia[1].

Product Specifications

CAS Number

[2732969-67-2]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; c-Fms; c-Kit; FGFR; FLT3; PDGFR; PROTACs; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pomalidomide-c5-dovitinib.html

Solubility

10 mM in DMSO

Smiles

O=C1NC2=C(C(N)=C1C3=NC4=CC=C(N5CCN(CC5)C(CCCCCNC6=CC=CC(C(N7C8C(NC(CC8)=O)=O)=O)=C6C7=O)=O)C=C4N3)C(F)=CC=C2

Molecular Formula

C39H38FN9O6

Molecular Weight

747.77

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Cao S, et al. Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells. J Med Chem. 2021;64 (22) :16497-16511.